The global cancer biomarkers market size was valued at USD 10.3 billion in 2016 and is estimated to grow at a compound annual growth rate (CAGR) of 14.3% from 2018 to 2025. Growing prevalence of malignancies coupled with increasing focus on development of targeted therapies is a major factor affirming the positive growth of this market.
Cancer is reported to be the second leading cause of mortality in the U.S. after cardiovascular disorders. Prevalence of breast, prostate, and lung malignancies has increased at a very steep rate with an estimated number of over 1,600 people being affected in the U.S. every year. In 2017, around 200,000 cases of breast cancer have been reported in the U.S.
U.S. cancer biomarkers market, by application, 2014 - 2025 (USD Billion)
Increasing awareness amongst patients and healthcare professionals about the importance of early diagnosis of malignancies and rising demand for personalized medicine is anticipated to provide this cancer biomarker market with high growth opportunities in the coming decade. Diagnostic biomarkers for early diagnosis enable doctors on deciding better treatment alternatives leading to successful recovery in lesser time.
In addition, increasing regulatory approval of novel drugs and diagnostics pertaining to cancer biomarkers is estimated to increase the adoption rate. For instance, in 2016, Epigenomics AG, a company involved in the development of a novel epigenetic biomarker test announced that its Epi proColon was included by the Chinese government for colorectal cancer (CRC) screening.
Based on type, the market is categorized into breast, prostate, colorectal, cervical, liver, and lung. Breast cancer was the largest segment in 2016. Breast, lung, and prostate cancer cumulatively held the revenue share of over 40% in 2016. Increasing awareness about early testing and growing base of target population are the key factors contributing toward dominance
On the other hand, lung cancer is expected to witness the fastest growth over the forecast period. Growing number of diagnostic tests targeting EGFR and BRAF mutations, which act as an essential biomarker for diagnosis of non-small cell lung cancer are anticipated to accentuate the segment growth.
Based on the biomolecule, the market is further segmented into genetic, epigenetic, metabolic, and proteomic biomarkers. Genetic biomarkers owing to their extensive usage, high-reliability rate, and easier analysis held a significant market share. Over 85% of malignancies are reported to be detected with the help of genetic and proteomic biomarkers.
Epigenetics has gained high acceptance in the field of cancer diagnostics. High amount of research is being undertaken by many players for the analysis of key epigenetic modification related to cancer for further development of biomarkers targeting drugs. Increasing collaboration between and pharmaceutical companies for the development of novel drugs targeting epigenetic biomarkers is estimated to boost the growth of this segment.
Global cancer biomarkers market, by biomolecule, 2016 (%)
Cancer biomolecules find application in various fields such as drug discovery and development, diagnostics, and personalized medicine. Diagnostics were the key revenue-generating application of the market pertaining to factors such as increasing development of biomarker-based oncology tests with high specificity and sensitivity.
Personalized medicine owing to its increasing demand and rising awareness amongst healthcare professionals is anticipated to witness flourishing growth rate. Moreover, growing approval for companion diagnostic tests for cancer drugs is expected to affirm market growth.
North America dominated the regional segment followed closely by Europe. High adoption of innovative technology, presence of key pharmaceutical companies, established R&D infrastructure pertaining to the development of novel diagnostic products and increased demand for specific & early diagnostics are the major factors for the aforementioned dominance.
However, the Asia Pacific region owing to increasing prevalence of cancer, beneficial environment for clinical trials, and increasing government funding for supporting drug development programs is anticipated to witness lucrative CAGR over the forecast period. Moreover, growing focus of pharmaceutical companies over this region coupled with rising awareness for biomarker-based diagnosis is one of the high impact-rendering drivers for growth.
Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company are some of the key players of the market.
New product development, collaborative agreements with research institutes for the development of novel biomarkers and mergers & acquisitions of small players are the key strategies implemented by these players to attain a stable market position.
In March 2023, Servier announced partnership with QIAGEN to develop new mIDH1 companion diagnostic test to support Servier’s Hemato-Oncology Portfolio. It is a step towards the development of a new companion diagnostic test that can be used to identify patients with acute myeloid leukemia (AML).
In January 2022, Illumina entered into a co-development partnership with SomaLogic to strengthen the two leading companies in the field of biomarker research. Illumina, a leader in next-generation sequencing (NGS), while SomaLogic, a leader in protein biomarker discovery will together accelerate the clinical opportunities.
Report Attribute |
Details |
Revenue forecast in 2025 |
USD 33.7 billion |
Growth rate |
CAGR of 14.3% from 2018 to 2025 |
Base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Market representation |
Revenue in USD Billion & CAGR from 2016 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
Country scope |
U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer biomarker market on the basis of type, biomolecules, type, application, and region:
Type Outlook (Revenue, USD Billion; 2014 - 2025)
Breast cancer
Prostate cancer
Colorectal cancer
Cervical cancer
Liver cancer
Lung cancer
Others
Biomolecule Outlook (Revenue, USD Billion; 2014 - 2025)
Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Proteomic Biomarkers
Others
Application Outlook (Revenue, USD Billion; 2014 - 2025)
Drug discovery and Development
Diagnostics
Personalized medicine
Others
Regional Outlook (Revenue, USD Billion; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
China
Japan
Latin America
Mexico
Brazil
MEA
South Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.